| __timestamp | Dynavax Technologies Corporation | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 49315000 |
| Thursday, January 1, 2015 | 22180000 | 75043000 |
| Friday, January 1, 2016 | 37257000 | 83749000 |
| Sunday, January 1, 2017 | 27367000 | 122682000 |
| Monday, January 1, 2018 | 64770000 | 207761000 |
| Tuesday, January 1, 2019 | 74986000 | 284812000 |
| Wednesday, January 1, 2020 | 79256000 | 317875000 |
| Friday, January 1, 2021 | 100156000 | 282660000 |
| Saturday, January 1, 2022 | 131408000 | 451421000 |
| Sunday, January 1, 2023 | 152946000 | 481871000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing operational costs is crucial for success. Over the past decade, Sarepta Therapeutics, Inc. and Dynavax Technologies Corporation have demonstrated contrasting strategies in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Sarepta's SG&A expenses surged by approximately 878%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Dynavax's expenses grew by about 760%, indicating a more measured approach.
Sarepta's peak in 2023, with expenses reaching nearly 482 million, underscores its commitment to scaling operations. Meanwhile, Dynavax, with a 2023 figure of around 153 million, showcases a strategy focused on efficiency. This divergence highlights the varied paths companies can take in the biotech sector, balancing growth with cost management. As these companies continue to evolve, their SG&A strategies will remain pivotal in shaping their competitive edge.
Pfizer Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
Vertex Pharmaceuticals Incorporated vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Genmab A/S or Sarepta Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Dr. Reddy's Laboratories Limited vs Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Pharming Group N.V.
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.
Sarepta Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Sarepta Therapeutics, Inc. vs Veracyte, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation